OnCo
ideasIdea

Test drugs on freshly cut slices of the patient's own tumour

A thin slice of a tumour, kept alive for a few days, still contains the immune cells and scaffolding that lab-grown cells lose. Drugs can be tested on it directly.

Precision-cut tumour slices preserve native architecture, stroma, vasculature remnants and resident immune cells for several days, and have been used to measure responses to chemotherapy, targeted agents and immunotherapy with imaging and single-cell readouts. They avoid the selection and adaptation that occur during organoid derivation, at the cost of a short experimental window.

Hypothesis
Slice-culture drug response measured within 72 hours predicts clinical response with accuracy at least equal to organoids, and does so for the majority of patients rather than only those whose organoids grow.
Rationale
Organoid derivation succeeds in a variable fraction of samples and takes weeks, which excludes patients who need decisions now; slices work on almost every resection or core.
What would test it
Paired study on 100 resections: derive both slices and organoids, treat both with the patient's regimen, and compare success rate, turnaround time and clinical concordance.
Maturity
preclinical evidence
Who has to act
research
Cost to try
Small (under $1M)
Years to first evidence
3
Bottlenecks it attacks

Connected

5top

Pages like this

not linked directly; found by shared links